Mark A. Henderson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mark A. Henderson has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Achilles J. Fakiris
Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN
2 shared publicationsRobert D. Timmerman
Department of Radiation Oncology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
2 shared publications- Anand Mahadevan
Radiation Oncology, Geisinger Cancer Institute, Danville, USA
1 shared publication - Anna Maria Storniolo
Indiana University School of Medicine, Indianapolis, USA
1 shared publication - April F. Eichler
Massachusetts General Hospital Cancer Center, Boston, USA
1 shared publication - Beverly Moy
Massachusetts General Hospital, Boston, MA
1 shared publication
Latest Publications
- 7 November 2013
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 142 (2) , 405-414
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
Brain metastases are common in patients with advanced, Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer. We evaluated the maximum tolerated dose (MTD) and feasibility of lapatinib given concurrently with whole brain radiotherapy (WBRT). Eligible patients had (HER2)-positive breast cancer and ≥1 brain metastasis. Patients received lapatinib 750 mg twice on day one followed by 1000, 1250, or 1500 mg once daily. WBRT (37.5 Gy, 15 fractions) began 1–8 days after starting lapatinib. Lapatinib was continued through WBRT. Following WBRT, patients received trastuzumab 2 mg/kg weekly and lapatinib 1000 mg once daily. The regimen would be considered feasible if n = 2), diarrhea (n = 2), hypoxia (n = 1), and grade 4 pulmonary embolus (n = 2). Among 28 evaluable patients, the CNS objective response rate (ORR) was 79 % [95% confidence interval (CI) 59–92 %] by pre-specified volumetric criteria; 46 % remained progression-free (CNS or non-CNS) at 6 months. The study did not meet the pre-defined criteria for feasibility because of toxicity, although the relationship between study treatment and some DLTs was uncertain. Given the high ORR, concurrent lapatinib-WBRT could still be considered for future study with careful safety monitoring.
- 7 November 2013
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 142 (2) , 405-414
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
Brain metastases are common in patients with advanced, Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer. We evaluated the maximum tolerated dose (MTD) and feasibility of lapatinib given concurrently with whole brain radiotherapy (WBRT). Eligible patients had (HER2)-positive breast cancer and ≥1 brain metastasis. Patients received lapatinib 750 mg twice on day one followed by 1000, 1250, or 1500 mg once daily. WBRT (37.5 Gy, 15 fractions) began 1–8 days after starting lapatinib. Lapatinib was continued through WBRT. Following WBRT, patients received trastuzumab 2 mg/kg weekly and lapatinib 1000 mg once daily. The regimen would be considered feasible if n = 2), diarrhea (n = 2), hypoxia (n = 1), and grade 4 pulmonary embolus (n = 2). Among 28 evaluable patients, the CNS objective response rate (ORR) was 79 % [95% confidence interval (CI) 59–92 %] by pre-specified volumetric criteria; 46 % remained progression-free (CNS or non-CNS) at 6 months. The study did not meet the pre-defined criteria for feasibility because of toxicity, although the relationship between study treatment and some DLTs was uncertain. Given the high ORR, concurrent lapatinib-WBRT could still be considered for future study with careful safety monitoring.
- 1 March 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 76 (3) , 789-795
A Pilot Trial of Serial 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Medically Inoperable Stage I Non–Small-Cell Lung Cancer Treated With Hypofractionated Stereotactic Body Radiotherapy
- 1 March 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 76 (3) , 789-795
A Pilot Trial of Serial 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Medically Inoperable Stage I Non–Small-Cell Lung Cancer Treated With Hypofractionated Stereotactic Body Radiotherapy
- 24 March 2009
- Published by S. Karger AG in Stereotactic and Functional Neurosurgery
- Vol. 87 (3) , 161-167
Gamma Knife Stereotactic Radiosurgery for Low-Grade Astrocytomas
Patients with low-grade astrocytoma (LGA; 8 pilocytic astrocytomas, 2 subependymal giant cell astrocytomas, 2 fibrillary astrocytomas) were selected for treatment with gamma knife stereotactic radiosurgery (GKSRS) based on having a demarcated appearance on CT or MRI and the possibility of dose sparing of adjacent eloquent structures. A median dose of 13 Gy was prescribed to the 50% isodose line, which covered the gross tumor. The median patient age was 17.4 years. The median target volume was 4.4 cm3. With a median follow-up of 48.2 months, 4-year tumor control and overall survival were 77 and 83%, respectively. Only 2 patients experienced symptomatic treatment-related toxicity. GKSRS can provide local control in cases of unresectable or recurrent LGA with a low incidence of side effects in carefully selected patients.
- 24 March 2009
- Published by S. Karger AG in Stereotactic and Functional Neurosurgery
- Vol. 87 (3) , 161-167
Gamma Knife Stereotactic Radiosurgery for Low-Grade Astrocytomas
Patients with low-grade astrocytoma (LGA; 8 pilocytic astrocytomas, 2 subependymal giant cell astrocytomas, 2 fibrillary astrocytomas) were selected for treatment with gamma knife stereotactic radiosurgery (GKSRS) based on having a demarcated appearance on CT or MRI and the possibility of dose sparing of adjacent eloquent structures. A median dose of 13 Gy was prescribed to the 50% isodose line, which covered the gross tumor. The median patient age was 17.4 years. The median target volume was 4.4 cm3. With a median follow-up of 48.2 months, 4-year tumor control and overall survival were 77 and 83%, respectively. Only 2 patients experienced symptomatic treatment-related toxicity. GKSRS can provide local control in cases of unresectable or recurrent LGA with a low incidence of side effects in carefully selected patients.